Ho P C, Chan Y F, So W K, Yeung W S, Chan S T
Department of Obstetrics and Gynaecology, University of Hong Kong.
Asia Oceania J Obstet Gynaecol. 1993 Jun;19(2):159-63. doi: 10.1111/j.1447-0756.1993.tb00367.x.
The incidence of luteinizing hormone surge was studied in patients who were downregulated with a short protocol of gonadotrophin releasing hormone agonist before ovarian stimulation for assisted reproduction. Buserelin nasal spray 100 micrograms was given 5 times daily from day 2 of the cycle, followed by ovarian stimulation with human menopausal gonadotrophin and follicle stimulating hormone from day 3 onwards. Of the 159 cycles studied, luteinizing hormone surge was detected in 9 cycles (5.7%). The occurrence of LH surge was usually (67%) but not always associated with a fall in serum oestradiol level before administration of human chorionic gonadotrophin. None of the patients developed luteinizing hormone surge after day 10. Even in patients without luteinizing hormone surge the serum luteinizing hormone levels on the day of administration of hCG were significantly higher than those on day 2 before administration of buserelin. It is concluded that a short protocol with intranasal buserelin 500 micrograms per day is inadequate to suppress endogenous luteinizing hormone surge.
在辅助生殖卵巢刺激前采用促性腺激素释放激素激动剂短方案进行降调节的患者中,研究了促黄体生成素峰的发生率。从周期第2天起,每天5次给予100微克布舍瑞林鼻喷雾剂,从第3天起用人绝经期促性腺激素和促卵泡生成素进行卵巢刺激。在研究的159个周期中,9个周期(5.7%)检测到促黄体生成素峰。促黄体生成素峰的出现通常(67%)但并非总是与注射人绒毛膜促性腺激素前血清雌二醇水平下降相关。第10天后无一例患者出现促黄体生成素峰。即使在没有促黄体生成素峰的患者中,注射hCG当天的血清促黄体生成素水平也显著高于注射布舍瑞林前第2天的水平。结论是,每天500微克鼻内布舍瑞林的短方案不足以抑制内源性促黄体生成素峰。